Short answer
NovoCure Ltd (NVCR) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $174M (up 12.3% year over year) with net income of −$71M.
Q1 2026 key financials · XBRL
- Revenue
- $174M
- +12.3% YoY
- Net income
- −$71M
- −107.3% YoY
- Operating margin
- -38.7%
- Gross margin
- 77.6%
- EPS (diluted)
- −$0.62
- −100.0% YoY
Source: XBRL data from the NovoCure Ltd (NVCR) Q1 2026 10-Q on SEC EDGAR. USD.
NovoCure Ltd Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- MD&A introduction only; period ended March 31, 2026
- Revenue, profitability, segments, cash flow, guidance, and headwinds not provided
Risk Factors
- No risk-factors section provided; submitted text contains Items 2–6 and signatures only
- New Rule 10b5-1 plan adopted by director Asaf Danziger on March 4, 2026
- Plan covers purchases of 202,758 securities and sales of 610,942 securities
- Employment and termination agreements filed for Uri Weinberg, Nicolas Leupin, and Frank Leonard
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NovoCure Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.